within Pharmacolibrary.Drugs.ATC.G;

model G03AC09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.76,
    Cl             = 0.00018,
    adminDuration  = 600,
    adminMass      = 0.075 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0043,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.04,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03AC09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Desogestrel is a synthetic progestogen (progestin) used mainly as a hormonal contraceptive in oral tablets, either alone or combined with ethinyl estradiol. It is a third-generation progestin and is currently approved for use in many countries for female contraception.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult women (aged 18-35), receiving an oral dose of desogestrel as part of contraceptive regimen.</p><h4>References</h4><ol><li><p>McClamrock, HD, &amp; Adashi, EY (1993). Pharmacokinetics of desogestrel. <i>American journal of obstetrics and gynecology</i> 168(3 Pt 2) 1021–1028. DOI:<a href=&quot;https://doi.org/10.1016/0002-9378(93)90332-d&quot;>10.1016/0002-9378(93)90332-d</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8447355/&quot;>https://pubmed.ncbi.nlm.nih.gov/8447355</a></p></li><li><p>Archer, DF, et al., &amp; Lammers, P (1994). Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol. <i>Fertility and sterility</i> 61(4) 645–651. DOI:<a href=&quot;https://doi.org/10.1016/s0015-0282(16)56640-0&quot;>10.1016/s0015-0282(16)56640-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8150105/&quot;>https://pubmed.ncbi.nlm.nih.gov/8150105</a></p></li><li><p>Back, DJ, et al., &amp; Orme, ML (1987). Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. <i>Contraception</i> 35(6) 619–626. DOI:<a href=&quot;https://doi.org/10.1016/s0010-7824(87)80021-5&quot;>10.1016/s0010-7824(87)80021-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2959449/&quot;>https://pubmed.ncbi.nlm.nih.gov/2959449</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03AC09;
